Idioma:

Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection

Batty, Cole J. ; Heise, Mark T. ; Bachelder, Eric M. ; Ainslie, Kristy M.

Advanced drug delivery reviews, 2021-02, Vol.169, p.168-189 [Periódico revisado por pares]

Netherlands: Elsevier B.V

Texto completo disponível

Citações Citado por

Enviar para

Título:
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection
Autor: Batty, Cole J. ; Heise, Mark T. ; Bachelder, Eric M. ; Ainslie, Kristy M.
Assuntos: Adjuvant ; Adjuvants, Immunologic - chemical synthesis ; Adjuvants, Immunologic - therapeutic use ; Animals ; COVID-19 - immunology ; COVID-19 - prevention & control ; COVID-19 Vaccines - chemical synthesis ; COVID-19 Vaccines - therapeutic use ; DNA Vaccine ; Drug Compounding - methods ; Drug Compounding - trends ; Drug Development - methods ; Drug Development - trends ; Humans ; Lipid Nanoparticles ; mRNA vaccine ; Polyplexes ; Protein and DNA Vaccine ; Protein Nanoparticles ; Recombinant Proteins - chemical synthesis ; Recombinant Proteins - therapeutic use ; SARS-CoV-2 - drug effects ; SARS-CoV-2 - immunology ; Virus-like Particles
É parte de: Advanced drug delivery reviews, 2021-02, Vol.169, p.168-189
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
Descrição: The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an unprecedented effort toward the development of an effective and safe vaccine. Aided by extensive research efforts into characterizing and developing countermeasures towards prior coronavirus epidemics, as well as recent developments of diverse vaccine platform technologies, hundreds of vaccine candidates using dozens of delivery vehicles and routes have been proposed and evaluated preclinically. A high demand coupled with massive effort from researchers has led to the advancement of at least 31 candidate vaccines in clinical trials, many using platforms that have never before been approved for use in humans. This review will address the approach and requirements for a successful vaccine against SARS-CoV-2, the background of the myriad of vaccine platforms currently in clinical trials for COVID-19 prevention, and a summary of the present results of those trials. It concludes with a perspective on formulation problems which remain to be addressed in COVID-19 vaccine development and antigens or adjuvants which may be worth further investigation. [Display omitted]
Editor: Netherlands: Elsevier B.V
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection

Batty, Cole J. ; Heise, Mark T. ; Bachelder, Eric M. ; Ainslie, Kristy M.

Netherlands: Elsevier B.V

Buscando em bases de dados remotas. Favor aguardar.